Davis v. Saidro

CourtDistrict Court, S.D. California
DecidedJanuary 26, 2021
Docket3:18-cv-02838
StatusUnknown

This text of Davis v. Saidro (Davis v. Saidro) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Davis v. Saidro, (S.D. Cal. 2021).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 RONNELL DAVIS, Case No.: 18-CV-2838-LAB(WVG)

12 Plaintiff, REPORT AND 13 v. RECOMMENDATION ON DEFENDANTS’ MOTION FOR 14 SAIDRO et al., SUMMARY JUDGMENT 15 Defendants. [Doc. No. 12.] 16 17 18 19 Plaintiff, a California state prisoner proceeding pro se, brought this civil rights action 20 under 42 U.S.C. § 1983. Pending before the Court is Defendants’ motion for summary 21 judgment on the Complaint’s sole claim for violation of the Eighth Amendment. As 22 explained below, this Court RECOMMENDS the motion be GRANTED, that judgment be 23 entered in Defendants’ favor, and that the case be closed. 24 / / / 25 / / / 26 / / / 27 / / / 28 / / / 1 I. STATEMENTS OF FACTS 2 A. Defendants’ Statement of Facts1 3 On October 2, 2013, Plaintiff was diagnosed with deep vein thrombosis (DVT) in 4 his lower right leg. DVT is the formation of a blood clot in a deep vein. DVT may cause 5 symptoms such as pain and swelling in the affected area, and it also carries the risk of 6 pulmonary embolism (PE), whereby the clot detaches and becomes lodged in an artery that 7 supplies blood to the lungs. PE may be fatal. Five days after the DVT diagnosis, Plaintiff 8 was diagnosed with and treated for PE. Since that time, Plaintiff has been on warfarin 9 therapy to reduce the risk of recurring DVT or PE. 10 The goal of warfarin therapy is to decrease the tendency of the patient’s blood to 11 clot, thereby helping to prevent the formation of clots that could lead to DVT or PE. 12 However, care must be taken that the patient’s blood does not become too slow to clot. 13 Otherwise, the patient would be at risk for bleeding. Therefore, the blood’s ability to clot 14 is checked regularly and the dosage of warfarin adjusted accordingly. Prothrombin time 15 (PT) is a measure of the time it takes a clot to form. PT is usually expressed as a ratio to a 16 control sample, the International Normalization Ratio (INR). The average person not on 17 warfarin would have an INR of 1.0. The longer it takes the blood to clot, the higher the 18 INR. The target (therapeutic) range for a patient on warfarin therapy is generally between 19 2.0 and 3.0. If the level is lower (subtherapeutic), the patient is at an increased risk of 20 clotting and an embolism; if the level is higher (supratherapeutic), the patient is at an 21 increased risk of bleeding. 22 23 24 25 1 As of this writing, Plaintiff has not filed an opposition to the MSJ despite two extensions of the deadline to do so. (See Doc. Nos. 16, 20.) When the most recent deadline expired on 26 January 19, 2021 (Doc. No. 20), Plaintiff filed neither an opposition nor a request for 27 extension of time as he had filed twice previously. (See Doc. Nos. 15, 19.) Because Plaintiff did not file an opposition to the MSJ, Defendants’ version of facts stands as the only set of 28 1 Under guidelines issued by the California Correctional Health Care Services, 2 treating physicians are to consider placing a hold on warfarin therapy for any patient whose 3 INR exceeds 4.0. As long as the patient shows no signs of bleeding, physicians may 4 increase the frequency of INR testing and resume warfarin therapy once the INR returns to 5 the therapeutic range. However, if a patient shows signs of serious bleeding, health care 6 providers are advised to withhold warfarin and transfer the patient to a higher level of care. 7 In May 2015, Defendant Dr. Saidro became Plaintiff’s primary care physician at the 8 Richard J. Donovan Correctional Facility (“Donovan” or RJD”). She had primary 9 responsibility for Plaintiff’s health care, including managing his warfarin therapy in 10 conjunction with the anticoagulation clinic at RJD. 11 Dr. Dulatre is a staff pharmacist at Donovan. Since 2015, he has been the manager 12 of the RJD anticoagulation clinic. He manages the anticoagulation medications of inmates 13 by regular appointments, medical record review, and collaboration with other medical 14 providers at Donovan to optimize patients’ drug therapy. Dr. Dulatre is responsible for 15 determining the appropriate dosages of anticoagulants, including warfarin, based on his 16 regular monitoring of his patients’ INR levels. 17 On March 1, 2016, a blood test showed that Plaintiff had an INR of 4.1. Dr. Dulatre 18 received an automated alert that Plaintiff’s INR was excessively high. He consequently 19 ordered a one-day hold of Plaintiff’s warfarin in an effort to return his INR to the 20 therapeutic range. He scheduled Plaintiff for a follow-up appointment on March 8, 2016 21 and a blood draw on March 9, 2016 to recheck Plaintiff’s INR. However, Plaintiff refused 22 to go to the March 8 appointment and failed to go to the March 9 lab appointment. Dr. 23 Dulatre rescheduled the blood draw for March 11. Plaintiff also failed to show for that 24 appointment. 25 Dr. Dulatre became concerned that it was dangerous to continue Plaintiff on 26 warfarin, since Plaintiff’s refusals of blood draws made it impossible to determine whether 27 the high March 1 INR level had returned to the therapeutic range. After Plaintiff failed to 28 show for his rescheduled blood draw on March 11, Dr. Dulatre called Dr. Saidro and 1 expressed his concerns. Dr. Saidro had Plaintiff summoned to the clinic, where a nurse 2 explained to Plaintiff the reasons he needed to have his blood drawn. Plaintiff again refused 3 a blood draw and refused to sign a Refusal of Medical Treatment form. After the nurse 4 reported to Dr. Saidro that Plaintiff again refused a blood draw, Dr. Saidro ordered a stop 5 to Plaintiff’s warfarin. Plaintiff’s warfarin was stopped that day.2 Dr. Saidro planned to 6 restart Plaintiff’s warfarin once his INR could be verified as no longer excessively high. 7 Plaintiff then prepared a Form 7362 Request for Medical Treatment that he dated 8 March 11, 2016, but which was not received until March 12 and not reviewed until March 9 13. In it, Plaintiff claimed he was experiencing bloody stool and bruising on his thighs. 10 Both are symptoms of bleeding and are signs that Plaintiff’s blood was taking too long to 11 clot. Plaintiff was seen in the clinic on March 13 because these symptoms required urgent 12 care. A nurse evaluated Plaintiff and noted rapid heartbeat and rapid breathing. She 13 consulted Dr. Bates, the on-call physician in the clinic at the time. Dr. Bates ordered 14 Plaintiff to be taken to the hospital to rule out pulmonary embolism. 15 Medical records show that Plaintiff was first taken to Sharp Chula Vista hospital. X- 16 rays and a CT scan of the chest were both unremarkable and found both of Plaintiff’s lungs 17 were clear. Plaintiff was then transferred to Tri-City Hospital for further care. The 18 admitting physician noted that Plaintiff reported maroon stool the day before, but that was 19 not verified. Plaintiff also reported lower chest/upper abdomen pain. The physician further 20 noted that “[i]t is unclear if there is really much to do,” that he “will hold off any 21 anticoagulants for now” as a result of Plaintiff’s report of maroon stool and that Plaintiff 22 “has obviously ruled out for a PE and his presentation is not consistent with a pulmonary 23 embolism either.” 24 Further tests, including an ultrasound on March 14 and a stress test on March 15 25 were also unremarkable. Plaintiff was discharged on March 15, 2016. The discharge 26

27 2 Davis claims he did not receive warfarin beginning March 9, 2016. Medical records show 28 1 summary notes that Plaintiff’s complaint of shortness of breath had resolved and there was 2 no evidence of bleeding during his hospitalization. His complaint of chest and abdominal 3 pain was deemed “likely musculoskeletal” and improved. 4 Plaintiff returned to Donovan early in the morning of March 16, 2016.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Diebold, Inc.
369 U.S. 654 (Supreme Court, 1962)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Harlow v. Fitzgerald
457 U.S. 800 (Supreme Court, 1982)
Whitley v. Albers
475 U.S. 312 (Supreme Court, 1986)
Malley v. Briggs
475 U.S. 335 (Supreme Court, 1986)
Anderson v. Creighton
483 U.S. 635 (Supreme Court, 1987)
Pearson v. Callahan
555 U.S. 223 (Supreme Court, 2009)
Barbara P. Hutchinson v. United States of America
838 F.2d 390 (Ninth Circuit, 1988)
Taylor v. List
880 F.2d 1040 (Ninth Circuit, 1989)
Eric Sanchez v. Duane R. Vild
891 F.2d 240 (Ninth Circuit, 1989)
John C. McGuckin v. Dr. Smith John C. Medlen, Dr.
974 F.2d 1050 (Ninth Circuit, 1992)
Jackson v. City Of Bremerton
268 F.3d 646 (Ninth Circuit, 2001)
Gibson v. County of Washoe, Nevada
290 F.3d 1175 (Ninth Circuit, 2002)
Toguchi v. Soon Hwang Chung
391 F.3d 1051 (Ninth Circuit, 2004)
John Snow v. E.K. McDaniel
681 F.3d 978 (Ninth Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Davis v. Saidro, Counsel Stack Legal Research, https://law.counselstack.com/opinion/davis-v-saidro-casd-2021.